MedTrace Logo

Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2

NCT00931138 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2009-07-02

No results posted yet for this study

Summary

Randomized comparison of standard induction treatment with daunorubicin for 3 days and Idarubicin for 3 or 4 days in adult AML patients between 50 and 70 years. Study of maintenance treatment with IL2

Conditions

Interventions

DRUG

chemotherapy (Aracytine + Daunorubicin)

Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3

DRUG

chemotherapy (Aracytine + Daunorubicin)

Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3

DRUG

chemotherapy (Aracytine + Daunorubicin)

Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    collaborator OTHER

  • Acute Leukemia French Association

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-12-31
Completion
2006-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00931138 on ClinicalTrials.gov